Tidal Investments LLC Buys 14,872 Shares of DexCom, Inc. (NASDAQ:DXCM)

Tidal Investments LLC increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 68.0% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 36,742 shares of the medical device company’s stock after buying an additional 14,872 shares during the period. Tidal Investments LLC’s holdings in DexCom were worth $2,463,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also modified their holdings of the company. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of DexCom during the second quarter worth approximately $25,000. Sachetta LLC lifted its holdings in DexCom by 255.2% during the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock worth $27,000 after purchasing an additional 171 shares during the last quarter. DT Investment Partners LLC boosted its stake in DexCom by 492.2% in the 2nd quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock valued at $43,000 after purchasing an additional 315 shares during the period. Riverview Trust Co grew its holdings in DexCom by 100.4% in the 3rd quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock valued at $31,000 after buying an additional 232 shares in the last quarter. Finally, Rothschild Investment LLC acquired a new position in DexCom in the 2nd quarter valued at $78,000. Institutional investors own 97.75% of the company’s stock.

DexCom Trading Down 2.2 %

Shares of DexCom stock opened at $77.19 on Monday. The firm’s 50 day moving average is $73.76 and its 200 day moving average is $84.04. The firm has a market capitalization of $30.15 billion, a PE ratio of 46.22, a price-to-earnings-growth ratio of 2.46 and a beta of 1.12. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $142.00. The company has a current ratio of 2.46, a quick ratio of 2.12 and a debt-to-equity ratio of 1.23.

Insider Buying and Selling at DexCom

In other news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction dated Wednesday, November 20th. The stock was sold at an average price of $74.73, for a total transaction of $318,275.07. Following the sale, the executive vice president now directly owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. This trade represents a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 0.30% of the company’s stock.

Wall Street Analysts Forecast Growth

DXCM has been the subject of a number of recent research reports. Royal Bank of Canada reduced their target price on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Raymond James cut their price objective on shares of DexCom from $115.00 to $99.00 and set a “strong-buy” rating for the company in a report on Friday, October 25th. Leerink Partners lowered their target price on shares of DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Citigroup boosted their price target on DexCom from $85.00 to $91.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Finally, Sanford C. Bernstein raised their price objective on DexCom from $82.00 to $86.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, DexCom presently has a consensus rating of “Moderate Buy” and a consensus price target of $98.00.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.